Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

21. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial Full Text available with Trip Pro

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) cohort.LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, controlled trial. Participants aged ≥50 years with type 2 diabetes and high cardiovascular risk were assigned 1:1 (...) to receive liraglutide (≤1.8 mg daily; n = 4,668) or placebo (n = 4,672) in addition to standard care and monitored for 3.5-5 years (median follow-up 3.8 years). The occurrence of neoplasms was a prespecified, exploratory secondary end point. Post hoc analyses of the time to the first confirmed neoplasms were conducted using a Cox regression model.Neoplasm was confirmed in 10.1% of patients with liraglutide versus 9.0% with placebo (hazard ratio [HR] 1.12 [95% CI 0.99; 1.28]). The HR (95% CI

2018 EvidenceUpdates

22. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial) Full Text available with Trip Pro

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial) Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (...) (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide vs 339 with placebo). This post hoc analysis characterized MIs (first and recurrent) occurring in LEADER, by treatment arm and regarding incidence, outcome, subtype, and troponin levels. A total of 780 MIs (first and recurrent) were reported, with fewer in the liraglutide-treatment group than in the placebo-treatment

2018 EvidenceUpdates

23. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis (Abstract)

Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant improvements in glycated haemoglobin (HbA1C) and body mass index (BMI). Based on these findings, the aim of the present study was to assess the long-term cost-effectiveness of switching from sitagliptin (...) to liraglutide in patients with type 2 diabetes in the UK.The IQVIA CORE Diabetes Model Version 8.5+ was used to project costs and clinical outcomes over patients' lifetimes. Baseline cohort characteristics and treatment effects were derived from the LIRA-SWITCH trial. Future costs and clinical benefits were discounted at 3.5% annually. Costs were accounted in pounds sterling (GBP) and expressed in 2016 values. One-way and probabilistic sensitivity analyses were performed.Model projections showed improved

2018 EvidenceUpdates

24. [Assessment of the LEADER study on liraglutide - rapid report]

[Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09. [Assessment of the LEADER study on liraglutide - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 530. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2018 Health Technology Assessment (HTA) Database.

25. Weekly semaglutide vs liraglutide efficacy and safety profile: a systematic review and network meta-analysis

Weekly semaglutide vs liraglutide efficacy and safety profile: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

26. Effects of liraglutide on liver fat: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Effects of liraglutide on liver fat: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

27. Liraglutide safety and efficacy in patients with Nonalcoholic Fatty Liver: A systematic review and meta-analysis

Liraglutide safety and efficacy in patients with Nonalcoholic Fatty Liver: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

28. The effects of liraglutide to women with polycystic ovary syndrome: a systematic review and meta-analysis

The effects of liraglutide to women with polycystic ovary syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

29. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Full Text available with Trip Pro

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. 30508430 2018 12 03 1539-3704 2018 Dec 04 Annals of internal medicine Ann. Intern. Med. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. 10.7326/M18-1569 Gilbert Matthew P MP Larner College of Medicine at The University of Vermont, South Burlington, Vermont (M.P.G.). Bain Stephen C SC Institute

2018 Annals of Internal Medicine Controlled trial quality: uncertain

30. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials Full Text available with Trip Pro

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0 mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat (...) ). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial

2017 EvidenceUpdates

31. Saxenda (liraglutide) - for treatment of overweight

Saxenda (liraglutide) - for treatment of overweight Saxenda® (liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Saxenda® (liraglutide) Conclusion Saxenda is indicated for treatment of overweight in people with a BMI >30 or a BMI between 27 and 30 with at least one weight-related complication as an adjunct to a reduced-calorie diet and physical activity. Saxenda contains liraglutide, a long-acting glucagon-like peptide-1 (GLP-1 analogue (...) ) and is administered subcutaneously once daily. The dose is escalated over a period of four weeks to the daily maintenance dose of 3 mg liraglutide. Saxenda's exact mechanism of action in weight loss is not entirely clear. Overall, treatment with Saxenda produces a placebo-adjusted weight loss of 5.2%. The weight loss achieved was statistically significantly greater in women compared to men. Saxenda treatment gave a continuous decrease in weight during the first 40 weeks of treatment, after which the weight loss

2017 Danish Pharmacotherapy Reviews

32. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial (Abstract)

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial Women with polycystic ovary syndrome (PCOS) were treated with the GLP-1 receptor agonist liraglutide to investigate the effect on liver fat content, visceral adipose tissue (VAT) and the prevalence of nonalcoholic fatty liver disease (NAFLD). In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated (...) with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks. Liver fat content was assessed by 1 HMR spectroscopy, VAT by MRI, body composition by DXA, and glucose metabolism by oral glucose tolerance test. Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01). Sex-hormone-binding-globulin (SHBG) levels increased by 19% (P = .03), and free testosterone decreased by 19% (P = .054

2017 EvidenceUpdates

33. Liraglutide and Renal Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Liraglutide and Renal Outcomes in Type 2 Diabetes. In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes (...) in patients with type 2 diabetes are unknown.We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach

2017 NEJM Controlled trial quality: predicted high

34. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.To determine the effects (...) of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders.This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through

2017 EvidenceUpdates

35. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used Full Text available with Trip Pro

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used To re-analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which the once-daily, fixed ratio combination of insulin degludec/liraglutide (IDegLira) was compared with basal insulin therapy.Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic (...) hypoglycaemia definitions, rates were consistently lower with IDegLira vs insulin degludec (IDeg) and IGlar U100. Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time. The definitions of confirmed and ADA-documented symptomatic hypoglycaemia did not have a significant effect on the treatment difference between IDegLira and IDeg, liraglutide

2017 EvidenceUpdates

36. Obese, overweight with risk factors: liraglutide (Saxenda)

Obese, overweight with risk factors: liraglutide (Saxenda) Obese, o Obese, ov verweight with risk factors: lir erweight with risk factors: liraglutide aglutide (Sax (Saxenda) enda) Evidence summary Published: 27 June 2017 nice.org.uk/guidance/es14 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2017. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory (...) status: Regulatory status: New medicine. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide (Saxenda) received a European marketing authorisation in March 2015 and was launched in the UK in January 2017. It is licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of: 30 kg/m² or more (obese), or from 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight

2017 National Institute for Health and Clinical Excellence - Advice

37. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program Full Text available with Trip Pro

Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program To describe amylase/lipase activity levels and events of acute pancreatitis (AP) in the SCALE (Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes) weight-management trials.Secondary analyses were performed on pooled data (...) from four trials (N = 5,358 with BMI ≥30, or 27 to <30 kg/m2 with ≥1 comorbidity). Of these, 1,723 had normoglycemia, 2,789 had prediabetes, and 846 had type 2 diabetes. Participants were randomized to liraglutide 3.0 mg (n = 3,302), liraglutide 1.8 mg (n = 211, only type 2 diabetes), or placebo (n = 1,845). Relationships between baseline characteristics and amylase/lipase activity at baseline and during treatment were investigated.Over 56 weeks, liraglutide 3.0 mg versus placebo was associated

2017 EvidenceUpdates

38. Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures Full Text available with Trip Pro

Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures 28827991 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures. 752-754 10.17179/excli2017-283 Gupta Gaurav G School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. School of Medicine and Public

2017 EXCLI journal

39. Recent update on biological activities and pharmacological actions of liraglutide Full Text available with Trip Pro

Recent update on biological activities and pharmacological actions of liraglutide 28827989 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Recent update on biological activities and pharmacological actions of liraglutide. 742-747 10.17179/excli2017-323 Tiwari Juhi J School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. Gupta Gaurav G School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. School of Medicine and Public Health, University

2017 EXCLI journal

40. Diabetes: avoid insulin degludec in combination with liraglutide

Diabetes: avoid insulin degludec in combination with liraglutide Prescrire IN ENGLISH - Spotlight ''Diabetes: avoid insulin degludec in combination with liraglutide'', 1 May 2017 {1} {1} {1} | | > > > Diabetes: avoid insulin degludec in combination with liraglutide Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Diabetes: avoid insulin degludec (...) in combination with liraglutide In patients with type 2 diabetes, the combination of insulin degludec and liraglutide in an injection pen has more disadvantages than advantages. In patients with type 2 diabetes, when metformin does not provide satisfactory glycaemic control, there is no evidence that the combination of liraglutide with an insulin is of any benefit in preventing clinical complications of diabetes. A fixed-dose combination in an injection pen of insulin degludec, a long-acting insulin

2017 Prescrire